Latest Breaking News On - Yannick pletan - Page 1 : comparemela.com

Acticor Biotech: Phase 2/3 study fails - MarketScreener

Acticor Biotech announced on Thursday that a Phase 2/3 clinical trial had failed to meet its endpoints in the treatment of stroke, resulting in a suspension of its share price.The biopharmaceutical.

Yannick pletanActicor biotechChief operating officerChief medical officer

Acticor Biotech: The UK Regulatory Agency (MHRA) Approved the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks

Acticor Biotech: The UK Regulatory Agency (MHRA) Approved the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Baden wübergUnited kingdomWest midlandsUnited kingdom generalJon townendNewton biocapitalMark thomasYannick pletanTim mayoFrench national institute of healthBirmingham health partnersInstitute of cardiovascular sciencesConsultant cardiologist at university hospitals birminghamUniversity of birminghamMidlands academic health science networkVenture investment

Acticor Biotech enrolls patient in study for acute ischemic stroke

The first U.S. patient was enrolled in a study evaluating glenzocimab in those with acute ischemic stroke.

United statesUnited kingdomCzech republicGreat britainYannick pletanRuchir shahNeuroscience centerEuropean patent officeEuropean medicines agencyDrug administrationActicor biotechPriority medicines

ACTICOR BIOTECH: Acticor Biotech obtains PRIME status from the European Medicines Agency for glenzocimab in the treatment of stroke

ACTICOR BIOTECH: Acticor Biotech obtains PRIME status from the European Medicines Agency for glenzocimab in the treatment of stroke
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNewton biocapitalYannick pletanVenture investmentFrench national institute of healthEuropean medicines agencyDrug administrationActicor biotechGeneral managerFrench national instituteMedical researchMirae asset capitalPrimer capitalEuronext growth paris

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalNewton biocapitalYannick pletanVenture investmentFrench national institute of healthEuropean medicines agencyDrug administrationActicor biotechGeneral managerFrench national instituteMedical researchMirae asset capitalPrimer capitalEuronext growth paris